BLACKSBURG, Va., March 6 -- Virginia Polytechnic Institute and State University issued the following news release:
Cancer researchers are making strides in efforts to use genetic profiling to develop a more precise understanding of the response to treatment of acute myeloid leukemia (AML), a rare but aggressive blood cancer.
In the most recent of a series of four studies featured inBone Marrow Transplantation, researchers have found that a highly sensitive DNA-based test can help doctors predict which patients with AML are most likely to relapse.
AML is an aggressive blood cancer, and about 30 percent of adults with the disease have a mutation in a gene called NPM1. Many of these patients undergo an allogeneic stem cell transplant - a pr...